<DOC>
	<DOCNO>NCT00003914</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness dolastatin 10 treat patient advanced kidney cancer .</brief_summary>
	<brief_title>Dolastatin 10 Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate dolastatin 10 patient advanced renal cell carcinoma . II . Describe toxicity regimen patient population . III . Assess development peripheral neuropathy patient population use regimen . IV . Assess limit sample pharmacokinetics correlate toxicity patient . OUTLINE : Patients receive dolastatin 10 IV every 3 week . Treatment continue least 4 course absence disease progression unacceptable toxicity . Patients document complete response receive additional 2 course , may receive retreatment time progression discretion investigator . Patients follow every 3 month 3 year . PROJECTED ACCRUAL : A total 15-30 patient accrue study 4-15 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Dolastatin 10</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma consider incurable surgery amenable radiation therapy curative intent Locally advance disease OR Locally recurrent disease OR Metastatic disease No transitional cell carcinoma Measurable disease No CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : AST le 3 time upper limit normal ( ULN ) Bilirubin normal Renal : Creatinine le 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Metabolic : Oral intake least 1,200 calorie per day Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No known seizure disorder No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No medical psychiatric condition would interfere compliance PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy No concurrent immunomodulating agent Chemotherapy : No prior chemotherapy renal cell carcinoma No concurrent cytostatic cytotoxic therapy Endocrine therapy : At least 4 week since prior hormonal therapy No concurrent hormonal agent Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy No prior radiotherapy great 15 % bone marrow No concurrent radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>